Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Genya Aharon-Hananel & Itamar Raz. (2019) An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. Expert Opinion on Pharmacotherapy 20:7, pages 781-790.
Read now
Read now
Articles from other publishers (27)
Xiaoqian Zhang, Jiale Zhang, Yan Ren, Ranran Sun & Xu Zhai. (2024) Unveiling the pathogenesis and therapeutic approaches for diabetic nephropathy: insights from panvascular diseases. Frontiers in Endocrinology 15.
Crossref
Crossref
Yujie Song, Yanzhen Tan, Meng Deng, Wenju Shan, Wenying Zheng, Bing Zhang, Jun Cui, Lele Feng, Lei Shi, Miao Zhang, Yingying Liu, Yang Sun & Wei Yi. (2023) Epicardial adipose tissue, metabolic disorders, and cardiovascular diseases: recent advances classified by research methodologies. MedComm 4:6.
Crossref
Crossref
Jiayu Lv, Yumeng Li, Shuqing Shi, Shixu Liu, Xia xu, Huaqin Wu, Bingxuan Zhang & Qingqiao Song. (2023) Frontier and Hotspot Evolution in Cardiorenal Syndrome: A Bibliometric Analysis From 2003 to 2022. Current Problems in Cardiology 48:8, pages 101238.
Crossref
Crossref
Xianghong Wang, Niujian Wu, Chuanchuan Sun, Donghua Jin & Hongyun Lu. (2023) Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome 15:1.
Crossref
Crossref
Daniel Edmonston, Matthew Sparks, Sudarshan Rajagopal & Myles Wolf. (2023) Sildenafil and Kidney Function in Heart Failure with Preserved Ejection Fraction. Kidney360 4:5, pages 631-640.
Crossref
Crossref
Guoqing Huang, Mingcai Li, Yan Li & Yushan Mao. (2022) Metabolomics: A New Tool to Reveal the Nature of Diabetic Kidney Disease. Laboratory Medicine 53:6, pages 545-551.
Crossref
Crossref
Xin Cao, Xiaojing Du, Heng Jiao, Quanlin An, Ruoxue Chen, Pengfei Fang, Jing Wang & Biao Yu. (2022) Carbohydrate-based drugs launched during 2000−2021. Acta Pharmaceutica Sinica B 12:10, pages 3783-3821.
Crossref
Crossref
Xie Lingli & Xia Wenfang. (2022) Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review. Life Sciences 300, pages 120543.
Crossref
Crossref
Ran Wei, Weihao Wang, Qi Pan & Lixin Guo. (2022) Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology 13.
Crossref
Crossref
Eiji Kutoh, Alexandra N. Kuto, Askuka Wada, Rumi Kurihara & Rina Kojima. (2021) Regulations of Free Fatty Acids and Diabetic Parameters in Drug
Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin
Monotherapy. Drug Research 72:02, pages 86-93.
Crossref
Crossref
Suiyuan Hu, Chu Lin, Xiaoling Cai, Xingyun Zhu, Fang Lv, Lin Nie & Linong Ji. (2022) The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology 12.
Crossref
Crossref
Mariana Tilinca, Robert Tiuca, Ioan Tilea & Andreea Varga. (2021) The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. Journal of Personalized Medicine 11:12, pages 1249.
Crossref
Crossref
Michaele B. Manigrasso, Piul Rabbani, Lander Egaña-Gorroño, Nosirudeen Quadri, Laura FryeBoyan Zhou, Sergey Reverdatto, Lisa S. Ramirez, Stephen DansereauJinhong PanHuilin Li, Vivette D. D’AgatiRavichandran Ramasamy, Robert J. DeVitaAlexander Shekhtman & Ann Marie Schmidt. (2021) Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Science Translational Medicine 13:621.
Crossref
Crossref
Miaobo Zhai, Xin Du, Changmei Liu & Huipu Xu. (2021) The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials. Frontiers in Clinical Diabetes and Healthcare 2.
Crossref
Crossref
Patrick Meagher, Robert Civitarese, Xavier Lee, Mark Gordon, Antoinette Bugyei-Twum, Jean-Francois Desjardins, Golam Kabir, Yanling Zhang, Hari Kosanam, Aylin Visram, Howard Leong-Poi, Andrew Advani & Kim A. Connelly. (2021) The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function. PLOS ONE 16:6, pages e0252711.
Crossref
Crossref
Yuya Itano, Hiroshi Sobajima, Norimi Ohashi, Taiga Shibata, Atsushi Fujiya, Takanobu Nagata, Masahiko Ando, Takahiro Imaizumi, Yoko Kubo, Takaya Ozeki, Takayuki Katsuno, Sawako Kato, Yoshinari Yasuda & Shoichi Maruyama. (2020) High urinary glucose is associated with improved renal prognosis in patients with diabetes mellitus. Journal of Diabetes Investigation 12:6, pages 998-1006.
Crossref
Crossref
Zsolt Szekeres, Kalman Toth & Eszter Szabados. (2021) The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites 11:2, pages 87.
Crossref
Crossref
Ichraf Slimani, Lamjed Mansour, Ismail Özdemir, Nevin Gürbüz & Naceur Hamdi. (2021) Synthesis, characterization and catalytic activity of PEPPSI-type palladium–NHC complexes. Inorganica Chimica Acta 515, pages 120043.
Crossref
Crossref
Carina Kirstine Klarskov, Helga Holm Schultz, Frederik Persson, Tomas Møller Christensen, Thomas Peter Almdal, Ole Snorgaard, Katrine Bagge Hansen, Ulrik Pedersen-Bjergaard & Peter Lommer Kristensen. (2020) Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment. BMC Endocrine Disorders 20:1.
Crossref
Crossref
K. Melissa Hallow, David W. Boulton, Robert C. Penland, Gabriel Helmlinger, Emily H. Nieves, Daniël H. van Raalte, Hiddo L. Heerspink & Peter J. Greasley. (2020) Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. Journal of Pharmacology and Experimental Therapeutics 375:1, pages 76-91.
Crossref
Crossref
Xiu Yang, Yuqian Li, Chongjian Wang, Zhenxing Mao, Wen Zhou, Lulu Zhang, Mengying Fan, Songyang Cui & Linlin Li. (2020) Meat and fish intake and type 2 diabetes: Dose–response meta-analysis of prospective cohort studies. Diabetes & Metabolism 46:5, pages 345-352.
Crossref
Crossref
M.C. Gómez García, J. Franch-Nadal, J.M. Millaruelo Trillo, F.X. Cos-Claramunt, L. Avila Lachica & P. Buil Cosiales. (2020) Control glucémico y de los factores de riesgo cardiovascular en los pacientes con diabetes tipo 2 con enfermedad cardiovascular en España, y su patrón de tratamiento, en función del género: Estudio CODICE. Medicina de Familia. SEMERGEN 46:2, pages 125-135.
Crossref
Crossref
Canan ERSOY. (2020) SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control. Turkish Journal of Internal Medicine 2:1, pages 1-4.
Crossref
Crossref
Andrew Smith, Vadim Iablokov, Mariafrancesca Mazza, Sonia Guarnerio, Vanna Denti, Mariia Ivanova, Martina Stella, Isabella Piga, Clizia Chinello, Bram Heijs, Peter A. van Veelen, Hallgrimur Benediktsson, Daniel A. Muruve & Fulvio Magni. (2020) Detecting Proteomic Indicators to Distinguish Diabetic Nephropathy from Hypertensive Nephrosclerosis by Integrating Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging with High-Mass Accuracy Mass Spectrometry. Kidney and Blood Pressure Research 45:2, pages 233-248.
Crossref
Crossref
Ikaro Breder & Andrei C. Sposito. 2020. Obesity and Diabetes. Obesity and Diabetes
695
704
.
Daniela Stols-Gonçalves, G. Kees Hovingh, Max Nieuwdorp & Adriaan G. Holleboom. (2019) NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?. Trends in Endocrinology & Metabolism 30:12, pages 891-902.
Crossref
Crossref
Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Mikkel Wiberg, Niels Høgh Brandt, Peter Haulund Gæde, Peter Rossing, Jens Faber, Silvio Inzucchi, Finn Gustafsson & Caroline Michaela Kistorp. (2019) Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open 9:11, pages e029098.
Crossref
Crossref